Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Kancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe side effects, due to poor selectivity, have limited the clinical use of HDAC inhibitors in the treatment of cancer, despite their promising treatment efficacy. For this reason, the pharmaceutical industry is now looking for HDAC inhibitors displaying a higher level of selectivity within this family of enzymes. Kancera´s discovery of selective HDAC6 inhibitors may provide a solution to how physicians could take advantage of HDAC inhibitors in the treatment of cancer without causing the patient severe side effects.
There are currently two HDAC inhibitors on the market for the treatment of various forms of Tcell lymphoma. These inhibitors are active against several members of the HDAC family of enzymes leading to side effects including severe nausea and potentially an increased cardiovascular risk. Selective inhibition of HDAC6 is expected to reduce these side effects, while activity against cancer cells is maintained.
Kancera´s unexpected discovery of such selective HDAC6 inhibitors is the result of an incidental finding made following an EU-funded project against epigenetic targets for the treatment of parasitic diseases. Laboratory tests have shown that Kancera's inhibitors display a higher level of selectivity against the HDAC6 enzyme as compared to a competing inhibitor, ACY-1215. Kancera´s HDAC6 inhibitors have furthermore been shown to be able to kill cancer cells in vitro.
ACY-1215, developed by the Boston-based company Acetylon Pharmaceuticals, is currently in early clinical trials ( Phase 1b) for the treatment of multiple myeloma. In July 2013 it was announced that Celgene for a $100 million upfront cash payment received an option to acquire Acetylon Pharmaceuticals with ACY -1215 as their main asset.
Kancera now intends to file patent applications for these inhibitors and to further evaluate the potential of them in the treatment of cancer, including multiple myeloma.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
AB, Kancera. "Kancera announces the discovery of a new class of compounds against cancer." Medical News Today. MediLexicon, Intl., 4 Dec. 2013. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/269633>
AB, K. (2013, December 4). "Kancera announces the discovery of a new class of compounds against cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269633.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.